首页> 美国卫生研究院文献>Journal of Virology >Quasispecies Heterogeneity within the E1/E2 Region as a Pretreatment Variable during Pegylated Interferon Therapy of Chronic Hepatitis C Virus Infection
【2h】

Quasispecies Heterogeneity within the E1/E2 Region as a Pretreatment Variable during Pegylated Interferon Therapy of Chronic Hepatitis C Virus Infection

机译:E1 / E2区域内的准种异质性作为慢性丙型肝炎病毒感染的聚乙二醇干扰素治疗期间的预处理变量

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A series of 29 patients undergoing treatment for chronic hepatitis C virus (HCV) genotype 1 infection with pegylated alpha-2a interferon plus ribavirin were studied for patterns of response to antiviral therapy and viral quasispecies evolution. All patients were treatment naive and had chronic inflammation and fibrosis on biopsy. As part of an analysis of pretreatment variables that might affect the outcome of treatment, genetic heterogeneity within the viral E1-E2 glycoprotein region (nucleotides 851 to 2280) was assessed by sequencing 10 to 15 quasispecies clones per patient from serum-derived PCR products. Genetic parameters were examined with respect to response to therapy based on serum viral RNA loads at 12 weeks (early viral response) and at 24 weeks posttreatment (sustained viral response). Nucleotide and amino acid quasispecies complexities of the hypervariable region 1 (HVR-1) were less in the responder group in comparison to the nonresponder group at 12 weeks, and genetic diversity was also less both within and outside of the HVR-1, with the difference being most pronounced for the non-HVR-1 region of E2. However, these genetic parameters did not distinguish responders from nonresponders for sustained viral responses. Follow-up studies of genetic heterogeneity based on the HVR-1 in selected responders and nonresponders while on therapy revealed greater evolutionary drift in the responder subgroup. The pretreatment population sequences for the NS5A interferon sensitivity determinant region were also analyzed for all patients, but no correlations were found between treatment response and any distinct genetic markers. These findings support previous studies indicating a high level of genetic heterogeneity among chronically infected HCV patients. One interpretation of these data is that early viral responses are governed to some extent by viral factors, whereas sustained responses may be more influenced by host factors, in addition to effects of viral complexity and diversity.
机译:研究了一系列29名接受聚乙二醇化α-2a干扰素加利巴韦林治疗的慢性丙型肝炎病毒(HCV)基因型1感染患者的抗病毒治疗反应和病毒准种演变的模式。所有患者均未接受过治疗,活检时患有慢性炎症和纤维化。作为可能影响治疗结果的治疗前变量分析的一部分,通过对每位患者来自血清PCR产物的10至15个准种克隆进行测序,评估了病毒E1-E2糖蛋白区域(核苷酸851至2280)内的遗传异质性。基于在第12周(早期病毒应答)和在治疗后24周(持续病毒应答)的血清病毒RNA负荷,检查关于治疗应答的遗传参数。在12周时,反应者组中的高变区1(HVR-1)的核苷酸和氨基酸拟种复杂度低于无反应者组,并且HVR-1内部和外部的遗传多样性也较少。对于E2的非HVR-1区域,差异最为明显。但是,这些遗传参数不能区分响应者和非响应者,以实现持续的病毒反应。在选择的应答者和非应答者中,基于HVR-1的遗传异质性的后续研究在治疗时显示,应答者亚组的进化漂移更大。还对所有患者分析了NS5A干扰素敏感性决定簇区域的预处理人群序列,但在治疗反应与任何不同的遗传标记之间未发现相关性。这些发现支持了先前的研究,这些研究表明在慢性感染的HCV患者中遗传异质性很高。对这些数据的一种解释是,早期病毒反应在某种程度上受病毒因素支配,而持续反应可能除受病毒复杂性和多样性影响外,还受到宿主因素的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号